Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 29 of 29 entries
Sorted by: Best Match Show Resources per page
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Cancer cell

Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, Tippu Z, Farag S, Rogiers A, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Shum B, Gerard CL, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Yousaf N, Jhanji S, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S.
PMID: 34968417
Cancer Cell. 2021 Dec 29; doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29.

No abstract available.

Cite
Fendler A, Shepherd STC, Au L, et al. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2021;doi: 10.1016/j.ccell.2021.12.013.
Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Schmitt, A. M., Tippu, Z., Farag, S., Rogiers, A., Harvey, R., Carlyle, E., Edmonds, K., Del Rosario, L., Lingard, K., Mangwende, M., Holt, L., Ahmod, H., Korteweg, J., Foley, T., Barber, T., Emslie-Henry, A., Caulfield-Lynch, N., Byrne, F., Shum, B., Gerard, C. L., Deng, D., Kjaer, S., Song, O. R., Queval, C., Kavanagh, C., Wall, E. C., Carr, E. J., Namjou, S., Caidan, S., Gavrielides, M., MacRae, J. I., Kelly, G., Peat, K., Kelly, D., Murra, A., Kelly, K., O'Flaherty, M., Shea, R. L., Gardner, G., Murray, D., Yousaf, N., Jhanji, S., Van As, N., Young, K., Furness, A. J. S., Pickering, L., Beale, R., Swanton, C., Gandhi, S., Gamblin, S., Bauer, D. L. V., Kassiotis, G., Howell, M., Nicholson, E., Walker, S., Wilkinson, R. J., Larkin, J., Turajlic, S. (2021). Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer cell, . https://doi.org/10.1016/j.ccell.2021.12.013
Fendler, Annika, et al. "Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer." Cancer cell vol. (2021). doi: https://doi.org/10.1016/j.ccell.2021.12.013
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Schmitt AM, Tippu Z, Farag S, Rogiers A, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Barber T, Emslie-Henry A, Caulfield-Lynch N, Byrne F, Shum B, Gerard CL, Deng D, Kjaer S, Song OR, Queval C, Kavanagh C, Wall EC, Carr EJ, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Shea RL, Gardner G, Murray D, Yousaf N, Jhanji S, Van As N, Young K, Furness AJS, Pickering L, Beale R, Swanton C, Gandhi S, Gamblin S, Bauer DLV, Kassiotis G, Howell M, Nicholson E, Walker S, Wilkinson RJ, Larkin J, Turajlic S. Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell. 2021 Dec 29; doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29. PMID: 34968417.
Copy Download .nbib Format: NLM
Selective Autophagy Receptors in Antiviral Defense.

Trends in microbiology

Viret C, Duclaux-Loras R, Nancey S, Rozières A, Faure M.
PMID: 33678557
Trends Microbiol. 2021 Sep;29(9):798-810. doi: 10.1016/j.tim.2021.02.006. Epub 2021 Mar 04.

Autophagy ensures the degradation of cytosolic substrates by the lysosomal pathway. Cargoes destined to be eliminated are confined within double-membrane vesicles called autophagosomes, prior to fusion with endolysosomal vacuoles. Autophagy receptors selectively interact with cargoes and route them to...

Cite
Viret C, Duclaux-Loras R, Nancey S, et al. Selective Autophagy Receptors in Antiviral Defense. Trends Microbiol. 2021;29(9):798-810doi: 10.1016/j.tim.2021.02.006.
Viret, C., Duclaux-Loras, R., Nancey, S., Rozières, A., & Faure, M. (2021). Selective Autophagy Receptors in Antiviral Defense. Trends in microbiology, 29(9), 798-810. https://doi.org/10.1016/j.tim.2021.02.006
Viret, Christophe, et al. "Selective Autophagy Receptors in Antiviral Defense." Trends in microbiology vol. 29,9 (2021): 798-810. doi: https://doi.org/10.1016/j.tim.2021.02.006
Viret C, Duclaux-Loras R, Nancey S, Rozières A, Faure M. Selective Autophagy Receptors in Antiviral Defense. Trends Microbiol. 2021 Sep;29(9):798-810. doi: 10.1016/j.tim.2021.02.006. Epub 2021 Mar 04. PMID: 33678557.
Copy Download .nbib Format: NLM
Critical reappraisal of embryo quality as a predictive parameter for pregnancy outcome: a pilot study.

Facts, views & vision in ObGyn

Campo R, Binda MM, Van Kerkhoven G, Frederickx V, Serneels A, Roziers P, Lopes AS, Gordts S, Puttemans P, Gordts S.
PMID: 25009716
Facts Views Vis Obgyn. 2010;2(4):289-95.

AIM OF THE STUDY: Pilot study to analyse the efficacy and embryo morphology using a new human embryo culture medium (GM501) versus the conventional used medium (ISM1).METHODS: Over a four-month period, all patients at the Leuven Institute of Fertility...

Cite
Campo R, Binda MM, Van Kerkhoven G, et al. Critical reappraisal of embryo quality as a predictive parameter for pregnancy outcome: a pilot study. Facts Views Vis Obgyn. 2010;2(4):289-95
Campo, R., Binda, M. M., Van Kerkhoven, G., Frederickx, V., Serneels, A., Roziers, P., Lopes, A. S., Gordts, S., Puttemans, P., & Gordts, S. (2010). Critical reappraisal of embryo quality as a predictive parameter for pregnancy outcome: a pilot study. Facts, views & vision in ObGyn, 2(4), 289-95.
Campo, R, et al. "Critical reappraisal of embryo quality as a predictive parameter for pregnancy outcome: a pilot study." Facts, views & vision in ObGyn vol. 2,4 (2010): 289-95.
Campo R, Binda MM, Van Kerkhoven G, Frederickx V, Serneels A, Roziers P, Lopes AS, Gordts S, Puttemans P, Gordts S. Critical reappraisal of embryo quality as a predictive parameter for pregnancy outcome: a pilot study. Facts Views Vis Obgyn. 2010;2(4):289-95. PMID: 25009716; PMCID: PMC4086013.
Copy Download .nbib Format: NLM
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.

Cancers

Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B.
PMID: 33418936
Cancers (Basel). 2021 Jan 06;13(2). doi: 10.3390/cancers13020168.

BACKGROUND: Pembrolizumab improves the survival of patients with advanced melanoma. A comprehensive analysis of baseline variables that predict the benefit of pembrolizumab monotherapy has not been conducted.METHODS: Survival data of patients with advanced melanoma who were treated with pembrolizumab...

Cite
Awada G, Jansen Y, Schwarze JK, et al. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers (Basel). 2021;13(2)doi: 10.3390/cancers13020168.
Awada, G., Jansen, Y., Schwarze, J. K., Tijtgat, J., Hellinckx, L., Gondry, O., Vermeulen, S., Warren, S., Schats, K., van Dam, P. J., Kockx, M., Keyaerts, M., Everaert, H., Seremet, T., Rogiers, A., & Neyns, B. (2021). A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers, 13(2), . https://doi.org/10.3390/cancers13020168
Awada, Gil, et al. "A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab." Cancers vol. 13,2 (2021). doi: https://doi.org/10.3390/cancers13020168
Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers (Basel). 2021 Jan 06;13(2). doi: 10.3390/cancers13020168. PMID: 33418936; PMCID: PMC7825041.
Copy Download .nbib Format: NLM
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.

Nature cancer

Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Bazin J, Gordon W, Barber T, Emslie-Henry A, Xie W, Gerard CL, Deng D, Wall EC, Agua-Doce A, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Dowdie L, Ash N, Gronthoud F, Shea RL, Gardner G, Murray D, Kinnaird F, Cui W, Pascual J, Rodney S, Mencel J, Curtis O, Stephenson C, Robinson A, Oza B, Farag S, Leslie I, Rogiers A, Iyengar S, Ethell M, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, O'Brien M, Harrington K, Bhide S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Swanton C, Gandhi S, Gamblin S, Bauer DL, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S.
PMID: 34950880
Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27.

CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered 12 weeks apart. Seroconversion rates after two doses were...

Cite
Fendler A, Shepherd STC, Au L, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021;2:1321-1337doi: 10.1038/s43018-021-00274-w.
Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A. M., Joharatnam-Hogan, N., Shum, B., Tippu, Z., Rzeniewicz, K., Boos, L. A., Harvey, R., Carlyle, E., Edmonds, K., Del Rosario, L., Sarker, S., Lingard, K., Mangwende, M., Holt, L., Ahmod, H., Korteweg, J., Foley, T., Bazin, J., Gordon, W., Barber, T., Emslie-Henry, A., Xie, W., Gerard, C. L., Deng, D., Wall, E. C., Agua-Doce, A., Namjou, S., Caidan, S., Gavrielides, M., MacRae, J. I., Kelly, G., Peat, K., Kelly, D., Murra, A., Kelly, K., O'Flaherty, M., Dowdie, L., Ash, N., Gronthoud, F., Shea, R. L., Gardner, G., Murray, D., Kinnaird, F., Cui, W., Pascual, J., Rodney, S., Mencel, J., Curtis, O., Stephenson, C., Robinson, A., Oza, B., Farag, S., Leslie, I., Rogiers, A., Iyengar, S., Ethell, M., Messiou, C., Cunningham, D., Chau, I., Starling, N., Turner, N., Welsh, L., van As, N., Jones, R. L., Droney, J., Banerjee, S., Tatham, K. C., O'Brien, M., Harrington, K., Bhide, S., Okines, A., Reid, A., Young, K., Furness, A. J. S., Pickering, L., Swanton, C., Gandhi, S., Gamblin, S., Bauer, D. L., Kassiotis, G., Kumar, S., Yousaf, N., Jhanji, S., Nicholson, E., Howell, M., Walker, S., Wilkinson, R. J., Larkin, J., & Turajlic, S. (2021). Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nature cancer, 21321-1337. https://doi.org/10.1038/s43018-021-00274-w
Fendler, Annika, et al. "Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study." Nature cancer vol. 2 (2021): 1321-1337. doi: https://doi.org/10.1038/s43018-021-00274-w
Fendler A, Shepherd STC, Au L, Wilkinson KA, Wu M, Byrne F, Cerrone M, Schmitt AM, Joharatnam-Hogan N, Shum B, Tippu Z, Rzeniewicz K, Boos LA, Harvey R, Carlyle E, Edmonds K, Del Rosario L, Sarker S, Lingard K, Mangwende M, Holt L, Ahmod H, Korteweg J, Foley T, Bazin J, Gordon W, Barber T, Emslie-Henry A, Xie W, Gerard CL, Deng D, Wall EC, Agua-Doce A, Namjou S, Caidan S, Gavrielides M, MacRae JI, Kelly G, Peat K, Kelly D, Murra A, Kelly K, O'Flaherty M, Dowdie L, Ash N, Gronthoud F, Shea RL, Gardner G, Murray D, Kinnaird F, Cui W, Pascual J, Rodney S, Mencel J, Curtis O, Stephenson C, Robinson A, Oza B, Farag S, Leslie I, Rogiers A, Iyengar S, Ethell M, Messiou C, Cunningham D, Chau I, Starling N, Turner N, Welsh L, van As N, Jones RL, Droney J, Banerjee S, Tatham KC, O'Brien M, Harrington K, Bhide S, Okines A, Reid A, Young K, Furness AJS, Pickering L, Swanton C, Gandhi S, Gamblin S, Bauer DL, Kassiotis G, Kumar S, Yousaf N, Jhanji S, Nicholson E, Howell M, Walker S, Wilkinson RJ, Larkin J, Turajlic S. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021 Dec;2:1321-1337. doi: 10.1038/s43018-021-00274-w. Epub 2021 Oct 27. PMID: 34950880; PMCID: PMC7612125.
Copy Download .nbib Format: NLM
Showing 25 to 29 of 29 entries